Over 200 California Auctions End Today - Bid Now

Faster, better, safer: The latest in PET and SPECT

by Lisa Chamoff, Contributing Reporter | June 06, 2022
Molecular Imaging
From the June 2022 issue of HealthCare Business News magazine

The new software comes with a technology called Deep Fusion that allows users to fuse any number of image layers, from any modality, including PET-MR, PET-CT and SPECT in any combination. For the first time, 3D data from any modality, including volumes of interest (VOI), can be visualized in real time, and are fully interoperable in radiotherapy structure format, facilitating collaboration within oncology departments.

In the fall of last year, MILabs released its seventh generation of preclinical imaging systems. The new Series 7 platform is made up of five integrated scanners that can be delivered in any combination and facilitate many synergistic imaging protocols.

The system’s optical imaging can perform high-throughput imaging with high sensitivity, said Frederik Beekman, chief executive officer of MILabs.

“The new SPECT and PET supercluster technology provides random-free sensitivity of up to 15%,” Beekman said. “This enables [users] to see tiny radioactive lesions. This is a breakthrough, since other scanners cannot see those isotopes at a high resolution.”

The company will present its latest PET and SPECT technology at the SNMMI annual meeting this month.

MILabs’ G-SPECT clinical imaging system, which is still in development, now also has the capability to image high-energy isotopes and PET and SPECT tracers simultaneously.

“It is very difficult to see them with traditional SPECT,” Beekman said. “But with the G-SPECT, you will be able to see theragnostic agents go into the tumor. It is expected that this will allow [users] to calculate if there's enough to kill the tumor and that other organs are spared, so one will be able to personalize the treatment to make it optimal for the patient.”

Positron is planning to introduce a new PET-CT scanner. The company anticipates a 2022 release upon FDA certification later this year.

“Positron has been at the forefront of the dedicated PET only and SPECT cardiac market for decades,” said Aaron Hargrave, vice president and head of clinical applications at Positron. “The company’s expansion to offering a PET/CT system is an important step for Positron’s future. PET is the superior technology that is the key driver of the significant new demand in all areas of nuclear imaging diagnostics. Positron’s system will provide better-quality patient scans in a shorter period of time, with less discomfort to the patients, with better resolution and better sensitivity.”

Positron’s combination PET-CT will also allow them to enter the oncology and neurology markets, Hargrave said.

You Must Be Logged In To Post A Comment